High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 12, 2017, Pages 3277-3282

  Nowak, J ^a   Zander, E ^a   Stefanik, D ^a   Higgins, P G ^a,b   Roca, I ^c   Vila, J ^c   McConnell, M J ^d   Cisneros, J M ^d   Seifert, H ^a,b   Garnacho Montero, José ^d   Rosso Fernández, Clara ^d   Pachon Ibañez, Ma Eugenia ^d   Pulido, Marina ^d   Moreno, Patricia ^d   Antonelli, Massimo ^e   Dimopoulos, George ^f   Bou, German ^g   Poirel, Laurent ^h   Nordmann, Patrice ^h   Naas, Thierry ⁱ  

^a UNIVERSITY OF COLOGNE   (Germany)

^b German Center for Infection Research (DZIF)   (Germany)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^f Attiko University Hospital   (Greece)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h UNIVERSITY OF FRIBOURG   (Switzerland)

ⁱ BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CARBAPENEM; CARBAPENEMASE; CEFEPIME; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BROTH DILUTION; GREECE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MIC50; MIC90; MOLECULAR EPIDEMIOLOGY; MULTICENTER STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RESPIRATORY SYSTEM; SPAIN; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER INFECTION; DNA SEQUENCE; DRUG EFFECT; GENOTYPE; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR TYPING; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; GREECE; HUMANS; INCIDENCE; ITALY; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; PNEUMONIA, VENTILATOR-ASSOCIATED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SPAIN;

EID: 85042182893     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx322     Document Type: Article

References (34)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-82
2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-51
3. Kuo SC, Chang SC, Wang HY et al. Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect Dis 2012; 12: 200
4. Göttig S, Gruber TM, Higgins PG et al. Detection of pan drug-resistant Acinetobacter baumannii in Germany. J Antimicrob Chemother 2014; 69:2578
5. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. IntensiveCareMed2005; 31: 649-55
6. Vincent JL, Rello J, Marshall J et al; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9
7. Garnacho J, Sole-Violan J, Sa-Borges M et al. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: amatched cohort study. Crit Care Med 2003; 31: 2478-82
8. Sievert DM, Ricks P, Edwards JR et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1-14
9. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: ameta-analysis.J Crit Care2008; 23: 91-100
10. Kalil AC, Metersky ML, Klompas M et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society ofAmerica and The American Thoracic Society. Clin Infect Dis 2016 63: 575-82
11. Heyland DK, Dodek P, Muscedere J et al. Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36: 737-44
12. Enne VI, Personne Y, Grgic L et al. Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance. Curr Opin Pulm Med 2014; 20: 252-8
13. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for themanagement of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41
14. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenemsusceptible VAP. Clin Infect Dis 2003; 36: 1111-8
15. Kallel H, Hergafi L, Bahloul M et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: amatched case-control study. Intensive CareMed 2007; 33: 1162
16. Rosso-Fernández C, Garnacho-Montero J, Antonelli M et al; MagicBullet study group. Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macroproject funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. Trials 2015; 16: 102
17. Higgins PG, Dammhayn C, Hackel M et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-8
18. International Organization for Standardization. ISO 20776-1: 2006. Clinical Laboratory Testing and In Vitro Diagnostic Test Systems-Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Test Devices-Part 1: Reference Method for Testing the In Vitro Activity of Antimicrobial Agents Against Rapidly Growing Aerobic Bacteria Involved in Infectious Diseases. https://www.iso.org/obp/ui/#iso: std:iso:20776:-1:ed-1:v1:en
19. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint Tables for Interpretation of MICs and Zone Diameters. http://www. eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_ Breakpoint_Tables.xls
20. Heritier C, Poirel L, Fournier PE et al. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 4174-9
21. Zander E, Fernández-González A, Schleicher X et al. Worldwide dissemination of acquired carbapenem-hydrolysing class D β-lactamases in Acinetobacter spp. other than Acinetobacter baumannii. Int J Antimicrob Agents 2014; 43: 375-7
22. Villalón P, Valdezate S, Medina-Pascual MJ et al. Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain. J Clin Microbiol 2011; 49: 875-82
23. Gogou V, Pournaras S, Giannouli M et al. Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). J Antimicrob Chemother 2011; 66: 2767-72
24. Zander E, Nemec A, Seifert H et al. Association between β-lactamaseencoding bla(OXA-51) variants and DiversiLab rep-PCR-based typing of Acinetobacter baumannii isolates.J ClinMicrobiol 2012; 50: 1900-4
25. Schleicher X, Higgins PG, Wisplinghoff H et al. Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009). Clin Microbiol Infect 2013; 19: 737-42
26. Liakopoulos A, Miriagou V, Katsifas EA et al. Identification of OXA-23-producing Acinetobacter baumannii in Greece, 2010 to 2011. Euro Surveill 2012; 17: pii'20117
27. Mendes RE, Spanu T, Deshpande L et al. Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. Clin Microbiol Infect 2009; 15: 588-92
28. Espinal P, Macia MD, Roca I et al. First report of an OXA-23 carbapenemase-producing Acinetobacter baumannii clinical isolate related to Tn2006 in Spain. Antimicrob Agents Chemother 2013; 57: 589-91
29. Pournaras S, Markogiannakis A, Ikonomidis A et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 2006; 57: 557-61
30. Esposito S, Gioia R, De Simone G et al. Bacterial epidemiology and antimicrobial resistance in the surgery wards of a large teaching hospital in Southern Italy. Mediterr J Hematol Infect Dis 2015; 7: e2015040
31. Marco F, Dowzicky MJ. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.JGlobAntimicrobResist 2016; 6: 50-6
32. Vourli S, Dafopoulou K, Vrioni G et al. Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant. Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2017; 72: 2528-30
33. Pournaras S, Dafopoulou K, Del Franco M et al. Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study. Int J Antimicrob Agents 2017; 49: 749-53
34. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81